Aspirin for the Primary Prevention of Cardiovascular Events: A Summary of the Evidence for the U.S. Preventive Services Task Force

Figure 2. Results of the chi-square test for heterogeneity were 2.96 for coronary heart disease mortality, 5.36 for fatal and nonfatal stroke events, and 1.58 for all-cause mortality ( > 0.2 in all cases). BMD = British Male Doctors' Trial; HOT = Hypertension Optimal Treatment Trial; OR = odds ratio; PHS = Physicians' Health Study; PPP = Primary Prevention Project; TPT = Thrombosis Prevention Trial.
Figure 2. Results of the chi-square test for heterogeneity were 2.96 for coronary heart disease mortality, 5.36 for fatal and nonfatal stroke events, and 1.58 for all-cause mortality ( > 0.2 in all cases). BMD = British Male Doctors' Trial; HOT = Hypertension Optimal Treatment Trial; OR = odds ratio; PHS = Physicians' Health Study; PPP = Primary Prevention Project; TPT = Thrombosis Prevention Trial. Meta-analysis of the effect of aspirin on coronary heart disease mortality (top), fatal and nonfatal stroke events (middle), and all-cause mortality (bottom).P

This Article

  1. Ann Intern Med January 15, 2002 vol. 136 no. 2 161-172
  1. AbstractFREE
  2. Figures
  3. Full Text
  4. Full Text (PDF)

Current Issue

  1. December 1, 2009, 151 (11)
  1. Alert me to current issues